Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the Company's investigational intravenous interferon beta-1a is a strong anti-viral and anti-inflammatory agent, currently being tested in several Phase III studies around the world against COVID-19. Faron is based in Turku, Finland. Faron is listed on AIM under the ticker ‘FARN’ and Nasdaq First North Growth Market ("Nasdaq First North") under ticker FARON.